Skip to content

Effect of gonadotrophin releasing hormone analogue (GnRH-a) pretreatment on patients with repeated implantation failure: a randomized controlled trial

Effect of gonadotrophin releasing hormone analogue (GnRH-a) pretreatment on patients with repeated implantation failure: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018364
Enrollment
Unknown
Registered
2018-09-13
Start date
2018-09-17
Completion date
Unknown
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

A:HRT protocol
B:HRT protocol
C:GnRH-a-HRT protocol

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 39 Years

Inclusion criteria

Inclusion criteria: Group A: patients who is gonging to recieve TET treatment for the first time following cancel of fresh embryo transplantation because of eveluation of blood progesterone or OHSS prevention. Group B and Group C: repeated implantation failure patients:1. age<40; 2.patients failed to get pregnant after twice or more fresh ET or TET, or after more than 4 high quality embryos or 6 embryos was transplanted into uterine accumulatively;3. patients gonging to recieve TET treatment.

Exclusion criteria

Exclusion criteria: 1. chromosome anomalies; 2. abnormality of uterine: uterine malformation, intrauterine adhesions and endometrial polyp; 3. hydrosalpinx; 4. adenomyosis, endometriosis; 5. abnormal thyroid function; 6. antiphospholipid antibody syndrome.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;implantation rate;

Secondary

MeasureTime frame
ongoing pregnancy rate;early abortion rate;

Countries

China

Contacts

Public ContactWeiping Qian

Peking University Shenzhen Hospital

qianweipingsz@126.com+86 13823510806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026